Researchers at the University of Liverpool and Nagoya University uncovered new drug candidates with promising therapeutic potential.
New research highlights the results of phase 1/2 clinical trial involving the experimental drug treatment tofersen.
The study involved 161 people with ALS who were compared to 80 people who did not have the disease.
The proteins suggest a direct link between the rare neurological disease and dementia.